A hybrid discrete-continuum model of immune responses to SARS-CoV-2 infection in the lung alveolar region, with a focus on interferon induced innate responseArticle Published on 2022-12-212022-11-15 Journal: Journal of theoretical biology [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] adaptive alveolar alveolar cells antibodies antibody antibody concentration baseline Cell cell death Cellular automaton COVID-19 develop diffusion domain Efficacy Future Gas exchange healthy human lung Immune cell immune protection immune response Immunity infected cell Infection initial Innate innate immune Innate immunity innate response Interaction interferon interferons lung alveolar maintain manuscript mechanism Model multiple mechanism outcome Pneumonia produced profiles progression Result RNA copy SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant simulations. Spread Strains submitted switching T cells the SARS-CoV-2 virus two-dimensional type I Viral load virion virions [DOI] 10.1016/j.jtbi.2022.111293 PMC 바로가기
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyArticle Published on 2022-11-012022-11-15 Journal: The Lancet. Gastroenterology & Hepatology [Category] SARS, 진단, [키워드] adjusted age All participant anti-SARS-CoV-2 anti-TNF antibody Antibody binding antibody concentration Antibody concentrations approved available data boost booster case-control study combination therapy Concentration control group COVID-19 COVID-19 vaccine Diagnosis disease dose Evidence first dose geometric mean geometric mean ratio group groups had no healthy control healthy individuals heterologous vaccine homologous IBD Immunosuppressed immunosuppressed patient immunosuppressive Immunosuppressive treatment Infection Inflammatory bowel disease jak inhibitors multicentre multivariable nine no significant difference Older Older age participant Patient patients treated Pfizer Primary outcome receiving Receptor binding domain recipient recruited reduced regimen response S1 RBD SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination significantly significantly lower Support T-cell Response T-cell responses the healthy therapy Tofacitinib Treatment ulcerative colitis Vaccine vaccine dose vaccine doses vaccine-induced antibody response VIP were measured [DOI] 10.1016/S2468-1253(22)00274-6 PMC 바로가기
Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugsArticle Published on 2022-09-232022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, 치료기술, [키워드] acute respiratory syndrome adverse event antibody concentration axial spondyloarthritis biological disease-modifying drug BNT162b2 BNT162b2 vaccine booster booster doses booster vaccination clinical questionnaire Cohort cohorts comparable coronavirus disease Coronavirus-2 COVID-19 enrolled evaluated Evidence flow cytometric General population healthy control humoral IL-17 immune response Immune-mediated inflammatory disease immunogenicity individuals inhibitor inhibitors intracellular cytokine investigated male no difference outcome Patient patients patients treated peptide-based persistence prospective observational study Responder Safety SARS-CoV-2 Specific spondyloarthritis subgroups T-cell T-cell immune response T-cell Response therapy TNFα treated tumor necrosis factor-alpha vaccination vaccination. virus-neutralizing antibody were assessed [DOI] 10.3389/fimmu.2022.1010808 PMC 바로가기
Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third DoseArticle Published on 2022-09-212022-11-15 Journal: The Journal of Infectious Diseases [Category] SARS, 진단, [키워드] ACE2 ACE2 displacement acute respiratory syndrome Adults age antibody concentration benefit binding binding antibodies chronic health condition chronic health conditions circulating antibody comparable coronavirus coronavirus disease COVID-19 COVID-19 mRNA vaccines COVID-19 vaccine domain dose doses exceeded functional humoral Humoral immunity Humoral response humoral responses immune immunogenicity data less magnitude mount mRNA Older Older adults omicron reached response Result SARS-CoV-2 Spike protein strain Strong Vaccine vaccine dose vaccine doses viral neutralization viral neutralization. Virus neutralization [DOI] 10.1093/infdis/jiac199 PMC 바로가기
Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down SyndromeObservational Study Published on 2022-09-042022-10-05 Journal: The Journal of Infectious Diseases [Category] SARS, 임상, 진단, [키워드] acute respiratory syndrome age antibody concentration Antibody Response antibody response. BNT162b2 ChAdOx1 clinical coronavirus coronavirus 2 Course COVID-19 COVID-19 vaccination Decreased Down syndrome healthy control higher risk increase in increasing age Infection Messenger RNA Mortality mRNA mRNA vaccination prospective observational cohort respiratory response resulting risk SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 vaccination Trial Vaccinations [DOI] 10.1093/infdis/jiac235 PMC 바로가기 [Article Type] Observational Study
Feasibility Studies of Nebulized SARS-CoV-2 Neutralizing Antibody in Mice and Cynomolgus MonkeysArticle Published on 2022-09-012022-11-15 Journal: Pharmaceutical research [Category] COVID19(2023년), SARS, 진단, [키워드] aerosol alternative route animal model antibodies antibody antibody concentration approach caused Clinical studies Concentration demonstrated Diseases dose epithelial lining feasibility humanized monoclonal antibody inhalation intravenous Intravenous injection lung mice Mild Moderate COVID-19 Monkey nebulized Neutralizing neutralizing antibody pharmacokinetics. PRNT reached remained respiratory tract safety profile SARS-CoV-2 SARS-COV-2 infection serum shown single dose Transport treating COVID-19 was used [DOI] 10.1007/s11095-022-03340-9 PMC 바로가기
SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic InfectionArticle Published on 2022-08-312022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] anti-SARS-CoV-2 anti-SARS-CoV-2 antibody antibodies antibody antibody concentration Antigen benefit binding antibody booster dose circulating collected Concentration Correlate of protection correlated correlation COVID-19 COVID-19 vaccine detectable detectable anti-SARS-CoV-2 antibodies Efficacy estimate Evidence exceeded Guidance IgG immune Immunity include Infection Neutralizing Neutralizing antibodies new SARS-CoV-2 observation Postinfection postvaccination Prevent proportion protection Protective provide public health Quantitative recommendation SARS-CoV-2 SARS-COV-2 infection serum specimen standardized. study population Support symptomatic symptomatic infection vaccination variant virus strains with COVID-19 [DOI] 10.1128/spectrum.01247-22 PMC 바로가기
Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 VariantArticle Published on 2022-08-312022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome adaptive analyzed antibody antibody concentration arise B cell B.1.617.2 binding binding antibodies binding antibody binding antibody unit blood sample collected Concentration coronavirus correlated Decreased Delta delta variant greater HCW HCWs Health care worker immune responses Immunity immunoassay individual Infection injection interquartile range IQR less maintain median neutralization neutralize Neutralizing Neutralizing antibodies neutralizing antibody Neutralizing antibody response Neutralizing antibody titer neutralizing capacity Postinfection protection. Protective question recent reduction in Registered required responses SARS-CoV-2 severe disease T cell the SARS-CoV-2 Transmissibility two virus strains vaccination Vaccine variants were measured [DOI] 10.1128/spectrum.02706-21 PMC 바로가기
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trialClinical Trial Published on 2022-08-102022-10-06 Journal: The Lancet. Infectious Diseases [Category] SARS, 변종, 진단, [키워드] 1:1 Administered administration adverse event adverse events age amplifying analysed Analysis antibody concentration Antigen assigned available data BMI booster booster dose Breastfeeding Coalition Contraception COVID-19 pandemic diagnosis of COVID-19 dose Efficacy enrolled evaluated event Evidence exclusion geometric mean titre GMT group healthy homologous IgG immune response inactive increase in initial intramuscular Local Matrix-M median Medical conditions Novavax NVX-CoV2373 outcome participant per-protocol per-protocol population phase 2 trial phase 3 study Placebo placebo-controlled pregnant primary endpoint proportion Protein randomisation randomised Randomly reaction reactogenicity receive Recombinant spike protein recruited regimens Registered Safety SARS-CoV SARS-CoV-2 SARS-CoV-2 strain SARS-CoV-2 vaccine SARS-CoV-2 variant screened serum IgG single booster dose stratified Support the SARS-CoV-2 the vaccine titres Treatment Trial USA vaccination Vaccine variant were excluded women [DOI] 10.1016/S1473-3099(22)00420-0 PMC 바로가기 [Article Type] Clinical Trial
Measurements of Anti-SARS-CoV-2 Antibody Levels after Vaccination Using a SH-SAW BiosensorSH-SAW 바이오센서를 이용한 예방접종 후 Anti-SARS-CoV-2 항체 수치 측정Article Published on 2022-08-042022-09-12 Journal: Biosensors [Category] SARS, 진단, [키워드] adenovirus vaccine adverse effect Anti-SARS-CoV-2 S antibody antibody concentration biosensor Blood Blood clots BNT chronic disease coated with Concentration COVID-19 pandemic cut-off diagnostic system fatigue first vaccination Health help in vitro increasingly induce Level Local measurement Moderna MONITOR mRNA vaccines myocarditis Pain pandemic Patient prevalence of COVID-19 Prevent Protein reduce SARS-CoV-2 SARS-CoV-2 spike protein second vaccination SH-SAW biosensor vaccination Vaccinations Vaccine vaccine. was determined [DOI] 10.3390/bios12080599 PMC 바로가기 [Article Type] Article